Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of polymyxin B1 and B2

LUO Xue-mei,LI Mei-juan,ZHU Huai-jun,SHENG Wei,ZHANG Wei,CHENG Xiao-liang,GE Wei-hong

DOI: https://doi.org/10.13286/j.1001-5213.2023.06.05

2023-01-01

Abstract:OBJECTIVE A sensitive and rapid high performance liquid chromatography-tandem mass spectrometry（HPLC-MS/MS）method for simtaneous determination of polymyxin B1（PMB1）and polymyxin B2（PMB2）has been developed and validated.METHODS The plasma sample was deproteinized with methanol-acetonitrile-formic acid（80∶20∶0.5,V/V）which contained the internal standard（Polymyxin E1）.Chromatographic separation was performed on a Phenomenex Kinetex XB-C 18 （3.0 mm×50 mm, 2.6 μm）column with mobile phase of acetonitrile-0.1% formic acid solution using gradient elution at a flow rate of 0.3 mL·min -1 ;electrospray source ion（ESI）,multiple reaction monitoring（MRM）and positive ion scanning were used for the determination.RESULTS [M+3H] 3+ was chosen as the precursor ion for both PMB1 and PMB2 and the transitions of the deprotonated molecules were 402.1→101.1 for PMB1 and 397.5→391.5 for PMB2.The lower limits of quantification for PMB1 and PMB2 were 35 ng·mL -1 and 15 ng·mL -1 ,respectively.The intra-day and inter-day precision of PMB1 and PMB2 were all less than 15%.The method has good stability and was not affected by matrix effect.From all 24 patients samples, the C ss, avg and AUC 0-24h of PMB were（4.44±1.37）μg·mL -1 ,and（87.74±27.97）μg·mL -1 ·h, respectively.CONCLUSION This method is simple, rapid and sensitive, and has been validated to simultaneous determination of plasma PMB1 and PMB2 concentrations in patients receiving intravenous polymyxin B therapy.